Genelux (NASDAQ:GNLX) Price Target Lowered to $32.00 at HC Wainwright

Genelux (NASDAQ:GNLXFree Report) had its price objective reduced by HC Wainwright from $35.00 to $32.00 in a research report sent to investors on Tuesday, Benzinga reports. They currently have a buy rating on the stock.

Genelux Trading Up 0.2 %

Shares of GNLX stock opened at $5.25 on Tuesday. The stock has a 50 day simple moving average of $7.62 and a two-hundred day simple moving average of $13.25. Genelux has a fifty-two week low of $4.89 and a fifty-two week high of $40.98.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of GNLX. Woodward Diversified Capital LLC lifted its position in shares of Genelux by 2,326.2% during the 4th quarter. Woodward Diversified Capital LLC now owns 1,082,270 shares of the company’s stock valued at $15,163,000 after buying an additional 1,037,663 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Genelux by 1.8% during the 4th quarter. Vanguard Group Inc. now owns 998,810 shares of the company’s stock valued at $13,993,000 after buying an additional 17,817 shares during the last quarter. Provident Wealth Management LLC purchased a new position in shares of Genelux during the 3rd quarter valued at $8,211,000. AE Wealth Management LLC boosted its stake in Genelux by 1,370.0% in the 3rd quarter. AE Wealth Management LLC now owns 194,875 shares of the company’s stock worth $4,772,000 after purchasing an additional 181,618 shares during the period. Finally, Northern Trust Corp boosted its stake in Genelux by 2.0% in the 4th quarter. Northern Trust Corp now owns 164,083 shares of the company’s stock worth $2,299,000 after purchasing an additional 3,267 shares during the period. Hedge funds and other institutional investors own 37.33% of the company’s stock.

About Genelux

(Get Free Report)

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.

See Also

Receive News & Ratings for Genelux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genelux and related companies with MarketBeat.com's FREE daily email newsletter.